December 28, 2011

Immunomedics And UCB Announce Restructuring Of EPRATUZUMAB License Agreement

December 14, 2011

Immunomedics Awarded New Patent for Improved Cell Lines for Protein Therapeutic Manufacturing

December 13, 2011

Immunomedics Announces Results From Two Clinical Trials at Hematology Conference

December 12, 2011

Immunomedics Develops Novel Antibody-Based Therapeutics for Mantle Cell and Other Lymphomas

December 12, 2011

Immunomedics Reports Subcutaneous Injections of Low-Dose Veltuzumab Produced High Rates of Response in ITP

December 09, 2011

Immunomedics Creates Targeted Therapeutics for Solid Cancers

December 07, 2011

Immunomedics Announces Outcome of 2011 Annual Meeting of Stockholders

December 06, 2011

Immunomedics Presentations at the Oppenheimer 22nd Annual Healthcare Conference

November 16, 2011

Immunomedics Presentations at 2011 annual meeting of American Society of Hematology (ASH)

November 15, 2011

Immunomedics Awarded Additional U.S. Patent For Anti-CD20 Treatment Of Autoimmune Diseases

November 11, 2011

Immunomedics Receives Thomas Alva Edison Patent Award From Research & Development Council of New Jersey

November 8, 2011

Epratuzumab Phase IIb Data Demonstrated Sensitivity of BICLA, A Novel BILAG-Based Composite Endpoint

November 7, 2011

Immunomedics To Participate In Upcoming Conferences

November 4, 2011

Immunomedics Announces First Quarter Fiscal 2012 Results and Clinicl Program Developments

November 2, 2011

Immunomedics Announces FDA Allows Resumption Of Clivatuzumab Tetraxetan Clinical

October 11, 2011

Immunomedics Awarded U.S. Patent For Cytokine-Antibody

September 22, 2011

Immunomedics Announces Partial Clinical Hold on Clivatuzumab Tetraxetan Clinical Trial

September 12, 2011

Immunomedics to Present at 2011 UBS Global Life Sciences Conference

September 2, 2011

Immunomedics to Webscast Presentation at Stifel Nicolaus 2011 Healthcare Conference

August 24, 2011

Fiscal 2011 results announced

August 9, 2011

Immunomedics to present at Wedbush Securities 2011 Life Sciences Management Access Conference

July 19, 2011

Immunomedics awarded additional patent for PEGylation Method

June 27, 2011

Immunomedics receives third milestone payment from Nycomed

June 16, 2011

Immunomedics to present at 2011 Wells Fargo Securities Healthcare Conference

June 8, 2011

Immunomedics reports Advances With New Imaging Agent Developments For Positron Emission Tomography

June 7, 2011

Antibody-directed radiation therapy appears to improve response to standard-of-care for aggressive lymphoma

June 7, 2011

Immunomedics reports final survival data with Yttrium-90-Labeled Clivatuzumab Tetraxetan and low-dose Gemcitabine in advanced pancreatic cancer

June 6, 2011

Immunomedics reports first clinical results of new antibody directed radiation therapy for colorectal cancer

June 3, 2011

Immunomedics to present at Jefferies 2011 Global Healthcare Conference

June 2, 2011

Immunomedics announces presentations at the 16th Congress of the European Hematology Association

May 31, 2011

Immunomedics announces updates on 4 clinical trials will be provided at the Society of Nuclear Medicine’s 58th annual meeting

May 10, 2011

Immunomedics announces third quarter fiscal 2011 results and clinical program developments

May 3, 2011

Immunomedics to present at Bank of America Merrill Lynch 2011 Health Care Conference

May 2, 2011

Results from single dose escalation study of 90Y-Clivatuzumab Tetraxetan in advanced pancreatic cancer published

April 6, 2011

Immunomedics awarded US patent for Veltuzumab, company’s humanized anti-CD20 antibody in advanced clinical testing

April 6, 2011

Immunomedics announces preclinical results of TF2 for pretargeted imaging of colon cancer

April 5, 2011

Immunomedics presents new DNL-derived antibodies for mantle cell lymphoma at AARC annual meeting

April 5, 2011

Immunomedics reports progress on development of antibody-SN-38 conjugates at cancer meeting

April 4, 2011

Immunomedics develops new DNL-derived antibody-interferon conjugate for blood cancer treatment

March 28, 2011

Immunomedics to report on new antibody-SN-38 conjugates and diverse novel DNL agents at AARC 102nd annual meeting

March 24, 2011

Immunomedics awarded three US patents covering its cancer therapeutic product candidates and technologies

March 9, 2011

Immunomedics awarded two additional US patents for dock-and-lock technology

February 25, 2011

Immunomedics announces presentations at upcoming healthcare conferences

February 4, 2011

Immunomedics announces second quarter fiscal 2011 results and clinical program developments

January 24, 2011

Immunomedics reports first experimental studies combining antibody-drug conjugate with antibody-directed radiation therapy for pancreatic cancer

January 21, 2011

Immunomedics reports targeted therapy for advanced pancreatic cancer improves survival